Maraviroc clinical trials
Also written Selzentry and Celsentri.
How each study uses Maraviroc is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Maraviroc studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 6 Aug 2007 · SELZENTRY · NDA 022128 (FDA, Drugs@FDA)
- European Union
- 18 Sept 2007 · Celsentri · EMEA/H/C/000811 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
117 studies that test it; most in 2009 (17)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2007 | 6 |
| 2008 | 11 |
| 2009 | 17 |
| 2010 | 11 |
| 2011 | 12 |
| 2012 | 12 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 2 |
| 2017 | 8 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 26 · Other 92
ViiV Healthcare (22) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · University of California, San Francisco (4) · St Stephens Aids Trust (4) · University of Maryland, Baltimore (3) · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (3) · University of North Carolina, Chapel Hill (3) · Imperial College London (3)
Often tested with
Tested in the same studies.
Tenofovir (8) · Raltegravir (8) · Ritonavir (8) · Darunavir (7) · Emtricitabine (6) · Dolutegravir (4) · Fosamprenavir (3) · Etravirine (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test Maraviroc, phase 3 first.
- Dec 2026A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVIDPhase 2/3 · HealthBio, Inc.
- Nov 2026Antiviral Clinical Trial for Long Covid-19Phase 2 · Icahn School of Medicine at Mount Sinai
- Mar 2027Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without AntiretroviralsPhase 2 · Federal University of São Paulo
- Jul 2027Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...Phase 1/2 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses Maraviroc is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 118
- Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...RecruitingPhase 1/2National Cancer Institute (NCI)NCT05470491Written as Maraviroc
- Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without AntiretroviralsRecruitingPhase 2Federal University of São PauloNCT06805656Written as Maraviroc
- Anti-inflammation Treatment for Idiopathic Inflammatory MyopathiesNot yet recruitingPhase 4Chinese University of Hong KongNCT07668505Written as maraviroc (Selzentry, Celsentri)
- A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVIDNot yet recruitingPhase 2/3HealthBio, Inc.NCT06974084Written as Maraviroc (MVC)
- Antiviral Clinical Trial for Long Covid-19RecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT06511063Written as Selzentry
- This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft DysfunctionRecruitingPhase 2University of California, San FranciscoNCT06853223Written as Maraviroc
- Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After StrokeRecruitingPhase 2Emmanuel CarreraNCT07080567Written as Maraviroc
- The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After StrokeRecruitingPhase 2University of CalgaryNCT04789616Written as Maraviroc
- Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune RestorationCompletedPhase 2French National Agency for Research on AIDS and Viral HepatitisNCT00944541Written as maraviroc
- Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis ImmunophenotypesTerminatedNot applicableKevin F. GibsonNCT02134717Written as all subjects will receive maraviroc 300mg orally twice a day for 6 weeks
- Bone, Immunologic, and Virologic Effects of a Antiretroviral RegimenCompletedPhase 2Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT01400412Written as Maraviroc
- Maraviroc Efficacy for Hepatitis CCompletedPhase 4University of Maryland, BaltimoreNCT02881762Written as Maraviroc
- Maraviroc in Patients With Moderate and Severe COVID-19CompletedPhase 1Rhode Island HospitalNCT04435522Written as Maraviroc
- Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE TrialCompletedPhase 1University Hospital HeidelbergNCT04721301Written as Nivolumab plus Ipilimumab plus Maraviroc
- Effects of Maraviroc vs. Efavirenz on CD4/CD8 RatioCompletedPhase 3Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalNCT03178084Written as Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID
- Impact of CCR5 Blockade in HIV+ Kidney Transplant RecipientsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02741323Written as Maraviroc
- Safety of Maraviroc for Post-stroke DepressionCompletedPhase 2Tel-Aviv Sourasky Medical CenterNCT05932550Written as Maraviroc 300 mg
- Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV InfectionCompletedPhase 1/2SEARCH Research FoundationNCT02475915Written as Maraviroc
- R5 Integrase Study in HIV-1 Naive PatientsCompletedNot applicableUniversity of Maryland, BaltimoreNCT01204905Written as Raltegravir and Maraviroc in combination
- Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRCCompletedPhase 1University Hospital HeidelbergNCT03274804Written as Maraviroc
See all 118 studies that test Maraviroc →
Given beside what is tested · 6 — Maraviroc is usual care or a partner of the new treatment
- Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral ReservoirCompletedPhase 2Robert L. MurphyNCT00976404Written as ART intensification (maraviroc)
- Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving MaravirocCompletedPhase 4ViiV HealthcareNCT00853840Written as Maraviroc
- A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™CompletedPhase 1GlaxoSmithKlineNCT01597648Written as Maraviroc
- Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected SubjectsCompletedPhase 2/3ViiV HealthcareNCT00098306Written as Maraviroc (UK-427,857)
- A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in BelgiumWithdrawnPhase 1International Partnership for Microbicides, Inc.NCT01242579Written as Maraviroc/Dapivirine Gel
- Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected SubjectsCompletedPhase 2/3ViiV HealthcareNCT00098748Written as maraviroc (UK-427,857)
As the comparator · 2 — what is tested is compared with Maraviroc
- Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal RingCompletedPhase 1International Partnership for Microbicides, Inc.NCT01363037Written as Maraviroc Vaginal Ring
- A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in BelgiumWithdrawnPhase 1International Partnership for Microbicides, Inc.NCT01242579Written as Maraviroc/Dapivirine Gel
Codes
What other systems call Maraviroc · ClinicalTrials.gg INT006766
- MeSH (NLM) D000077592MaravirocConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) MD6P741W8AMARAVIROCConfirmed FDA, NLM, Wikidata
- RxNorm 620216Confirmed FDA, Wikidata
- Wikidata Q421369maravirocConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73144MaravirocOne source FDA
- DrugBank DB04835One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077592 | Maraviroc | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | MD6P741W8A | MARAVIROC | Confirmed FDA, NLM, Wikidata |
| RxNorm | 620216 | — | Confirmed FDA, Wikidata |
| Wikidata | Q421369 | maraviroc | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73144 | Maraviroc | One source FDA |
| DrugBank | DB04835 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.